ABMIUM target intelligence
BCR activator of RhoGEF and GTPase
BCR encodes breakpoint cluster region protein, a multidomain regulator of small GTPase signalling. This ABMIUM target record connects the human BCR reference identifiers with catalogue products that target BCR.
Read full target overviewABMIUM research catalogue
Loading products for BCR…
Research context & evidence
Target information is kept separate from product-level validation so you can review the biology and the reagent evidence independently.
BCR combines opposing regulatory activities toward small GTP-binding proteins. Its C-terminal GAP domain promotes GTP hydrolysis by RAC1, RAC2 and CDC42, while its central DH domain has guanine-nucleotide exchange activity toward CDC42, RHOA and RAC1. The amino terminus also has intrinsic kinase activity. BCR is additionally important because chromosomal rearrangement with ABL1 produces the BCR-ABL fusion associated with chronic myeloid leukaemia and other leukaemias.
BCR is studied in small-GTPase regulation, cytoskeletal signalling, cell motility and differentiation, and in the biology of BCR-ABL fusion-driven leukaemia. For reagent selection, distinguish assays intended for native BCR from those designed to detect a BCR-ABL fusion or a specific fusion breakpoint, and confirm species, epitope, application and product-level validation.
Names used across publications, databases and supplier catalogues.
